Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses

被引:115
作者
Draenert, R
Altfeld, M
Brander, C
Basgoz, N
Corcoran, C
Wurcel, AG
Stone, DR
Kalams, SA
Trocha, A
Addo, MM
Goulder, PJR
Walker, BD
机构
[1] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Div Aids, Boston, MA USA
[4] Lemuel Shattuck Hosp, Boston, MA USA
[5] John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England
关键词
CD8 and CD4 T cell responses; overlapping peptides; Elispot assay; intracellular cytokine staining assay;
D O I
10.1016/S0022-1759(02)00541-0
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Increasing efforts are directed towards the development of effective vaccines through induction of virus-specific T cell responses. Although emerging data indicate a significant role of these cells in determining viral set point in infections such as HIV, there is as yet no consensus as to the best methods for assaying the breadth of these responses. In this study, we used sensitive interferon gamma-based intracellular cytokine staining (ICS) and Elispot assays to-determine-the optimal overlapping peptide set to screen for these responses. Twenty persons with established HIV infection were studied, focusing on responses to the highly immunogenic Nef protein. Six different HIV-1 Nef peptide sets were used, ranging in length from 15 to 20 amino acids (aa), in overlap from 10 to 11 amino acids, and derived from two different B clade sequences. A total of 54 CD8 T cell responses to Nef peptides were found in this cohort, of which only 12 were detected using previously defined Nef optimal epitopes. No single peptide set detected all responses. Though there was a trend of the shorter peptides detecting more CD8 T cell responses than the 20 amino acid long peptides and longer peptides detecting more CD4 T cell responses, neither was statistically significant. There was no difference between an overlap of 10 or 11 amino acids. All responses detected with the six different sets of overlapping peptides were towards the more highly conserved regions of Nef. We conclude that peptides ranging from 15 to 20 amino acids yield similar results in IFN-gamma-based Elispot and ICS assays, and that all are likely to underestimate the true breadth of responses to a given reference strain of virus. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:19 / 29
页数:11
相关论文
共 23 条
  • [1] The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals
    Addo, MM
    Altfeld, M
    Rosenberg, ES
    Eldridge, RL
    Philips, MN
    Habeeb, K
    Khatri, A
    Brander, C
    Robbins, GK
    Mazzara, GP
    Goulder, PJR
    Walker, BD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (04) : 1781 - 1786
  • [2] A decaepitope polypeptide primes for multiple CD8+ IFN-γ and Th lymphocyte responses:: Evaluation of multiepitope polypeptides as a mode for vaccine delivery
    Alexander, J
    Oseroff, C
    Dahlberg, C
    Qin, MS
    Ishioka, G
    Beebe, M
    Fikes, J
    Newman, M
    Chesnut, RW
    Morton, PA
    Fok, K
    Appella, E
    Sette, A
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (12) : 6189 - 6198
  • [3] Vpr is preferentially targeted by CTL during HIV-1 infection
    Altfeld, M
    Addo, MM
    Eldridge, RL
    Yu, XG
    Thomas, S
    Khatri, A
    Strick, D
    Phillips, MN
    Cohen, GB
    Islam, SA
    Kalams, SA
    Brander, C
    Goulder, PJR
    Rosenberg, ES
    Walker, BD
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (05) : 2743 - 2752
  • [4] Identification of dominant optimal HLA-B60-and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: Rapid characterization of CTL responses by enzyme-linked immunospot assay
    Altfeld, MA
    Trocha, A
    Eldridge, RL
    Rosenberg, ES
    Phillips, MN
    Addo, MM
    Sekaly, RP
    Kalams, SA
    Burchett, SA
    McIntosh, K
    Walker, BD
    Goulder, PJR
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (18) : 8541 - 8549
  • [5] Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses:: Relationship to viral load in untreated HIV infection
    Betts, MR
    Ambrozak, DR
    Douek, DC
    Bonhoeffer, S
    Brenchley, JM
    Casazza, JP
    Koup, RA
    Picker, LJ
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (24) : 11983 - 11991
  • [6] Definition of an optimal cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma-associated herpesvirus kaposin protein
    Brander, C
    O'Connor, P
    Suscovich, T
    Jones, NG
    Lee, Y
    Kedes, D
    Ganem, D
    Martin, J
    Osmond, D
    Southwood, S
    Sette, A
    Walker, BD
    Scadden, DT
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (02) : 119 - 126
  • [7] Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene
    Casimiro, DR
    Tang, AM
    Perry, HC
    Long, RS
    Chen, MC
    Heidecker, GJ
    Davies, ME
    Freed, DC
    Persaud, NV
    Dubey, S
    Smith, JG
    Havlir, D
    Richman, D
    Chastain, MA
    Simon, AJ
    Fu, TM
    Emini, EA
    Shiver, JW
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (01) : 185 - 194
  • [8] DNA vaccination of macaques with several different Nef sequences induces multispecific T cell responses
    Couillin, I
    Letourneur, F
    Lefèbvre, P
    Guillet, JG
    Martinon, F
    [J]. VIROLOGY, 2001, 279 (01) : 136 - 145
  • [9] A SOLID-PHASE ENZYME-LINKED IMMUNOSPOT (ELISPOT) ASSAY FOR ENUMERATION OF SPECIFIC ANTIBODY-SECRETING CELLS
    CZERKINSKY, CC
    NILSSON, LA
    NYGREN, H
    OUCHTERLONY, O
    TARKOWSKI, A
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1983, 65 (1-2) : 109 - 121
  • [10] Weak anti-HIV CD8+ T-cell effector activity in HIV primary infection
    Dalod, M
    Dupuis, M
    Deschemin, JG
    Goujard, C
    Deveau, C
    Meyer, L
    Ngo, N
    Rouzioux, C
    Guillet, JG
    Delfraissy, JF
    Sinet, M
    Venet, A
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (10) : 1431 - 1439